Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedJul 8, 2015TPN 3:1, 997 ml with lipids BagsLack of Assurance of Sterility: Sterility of product is not assured.Lincare, Inc. · D-1155-2015Class IITerminatedJul 8, 2015TPN 3:1, 2000 mL BagsLack of Assurance of Sterility: Sterility of product is not assured.Lincare, Inc. · D-1154-2015Class IITerminatedJul 8, 2015TPN 3:1, 2250 mL BagsLack of Assurance of Sterility: Sterility of product is not assured.Lincare, Inc. · D-1153-2015Class IITerminatedJul 8, 2015TPN 3:1, 2400 mL BagLack of Assurance of Sterility: Sterility of product is not assured.Lincare, Inc. · D-1152-2015Class IITerminatedJul 8, 2015OXYCODONE HCl C-II TabletsSuperpotent Drug: Confirmed customer complaint of a single unit dose blister cavity containing 2 OXYCODONE HCl 5 mg tablets.The Harvard Drug Group, LLC · D-1150-2015Class IIITerminatedJul 1, 2015Dr Blue Pain Relieving GelSuperpotent Drug: Product may not be uniformly blended resulting in non-uniform distribution of the active ingredient menthol.Indiana Botanic Gardens, Inc · D-1149-2015Class IIITerminatedJul 1, 2015Lutera (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol tablets USP)Labeling: Incorrect or Missing Package Insert; Product is being recalled because the birth control packs were distributed with out-dated package inserts.Actavis Inc · D-1148-2015Class IIITerminatedJul 1, 2015E-Z-CAT Dry Barium Sulfate for SuspensionFailed stability specifications:This recall has been initiated due to out of specification results for viscosity.Bracco Diagnostic Inc · D-1147-2015Class IIITerminatedJun 24, 2015Amlodipine besylate and Atorvastatin calcium tabletsSubpotent drugDr. Reddy's Laboratories, Inc. · D-1146-2015Class IIITerminatedJun 24, 2015Amlodipine besylate and Atorvastatin calcium tabletsSubpotent drugDr. Reddy's Laboratories, Inc. · D-1145-2015Class IIITerminatedJun 24, 2015Amlodipine besylate and Atorvastatin calcium tabletsSubpotent drugDr. Reddy's Laboratories, Inc. · D-1144-2015Class IIITerminatedJun 24, 2015Amlodipine besylate and Atorvastatin calcium tabletsSubpotent drugDr. Reddy's Laboratories, Inc. · D-1143-2015Class IIITerminatedJun 24, 2015Loratadine Orally Disintegrating Tablets USPSuperpotent Drug: Out Of Specification (OOS) result for Assay.Ohm Laboratories, Inc. · D-1142-2015Class IITerminatedJun 24, 2015NEXIUM¿Presence of Foreign Tablets/Capsules: Confimed customer compliant by a retail pharmacist that an unopened bottle labeled as NEXIUM¿ capsules contained 60 SEROQUEL¿ XR...AstraZeneca Pharmaceuticals LP · D-1141-2015Class IITerminatedJun 24, 2015Lamivudine and Zidovudine Tablets USP 150mg/300mg 30 Unit Dose BlistersFailed dissolution specificationsAmerican Health Packaging · D-1140-2015Class IIITerminatedJun 24, 2015Fentanyl Citrate InjFailed Impurities/Degradation Specifications; 12 month stability testing (Expansion of RES #70548).West-Ward Pharmaceutical Corp. · D-1139-2015Class IIITerminatedJun 24, 2015Foradil AerolizerFailed Stability Specification: out of specification result obtained for the Particle Size Distribution test during stability testing.Novartis Pharmaceuticals Corp. · D-1138-2015Class IIITerminatedJun 24, 2015Foradil AerolizerFailed Stability Specification: out of specification result obtained for the Particle Size Distribution test during stability testing.Novartis Pharmaceuticals Corp. · D-1137-2015Class IITerminatedJun 24, 2015Divalproex Sodium Extended-Release TabletsFailed Dissolution Specifications; exceeded specification at the 9 hour time pointDr. Reddy's Laboratories, Inc. · D-1136-2015Class IITerminatedJun 24, 2015Divalproex Sodium Extended-Release TabletsFailed Dissolution Specifications; exceeded specification at the 9 hour time pointDr. Reddy's Laboratories, Inc. · D-1135-2015Class IITerminatedJun 24, 2015Famotidine TabletsCGMP Deviations: Failure of the manufacturer, Wockhardt Ltd, to adequately investigate customer complaints.Allegiant Health · D-1134-2015Class IITerminatedJun 17, 2015PHENYLephrine HCl 50 mg in 0.9% Sodium Chloride 250 mL bagLabeling: Label Mix-Up: Product is incorrectly labeled as phenylephrine 50 mg in 0.9% sodium chloride rather than phenylephrine 50 mg in 5% dextrose.SCA Pharmaceuticals · D-1133-2015Class IITerminatedJun 17, 2015MD-GastroviewLabeling: incorrect or missing lot number and/or expiration dateMallinckrodt, Inc. · D-1132-2015Class IITerminatedJun 17, 2015Heparin Sodium and 0.9% Sodium Chloride InjectionSubpotent Drug; out of specification results for heparin raw materialBaxter Healthcare Corp · D-1131-2015Class IITerminatedJun 17, 2015Hydroxyzine HydrochlorideFailed Impurities/Degradation SpecificationsAkorn, Inc. · D-1130-2015Class IITerminatedJun 17, 2015Hydroxyzine HydrochlorideFailed Impurities/Degradation SpecificationsAkorn, Inc. · D-1129-2015Class IITerminatedJun 17, 2015AlprostadilLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1128-2015Class IITerminatedJun 17, 2015Trimix (PGE1Lack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1127-2015Class IITerminatedJun 17, 2015Trimix (PGE1Lack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1126-2015Class IITerminatedJun 17, 2015Trimix (ALack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1125-2015Class IITerminatedJun 17, 2015Trimix (ALack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1124-2015Class IITerminatedJun 17, 2015HyaluronidaseLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1123-2015Class IITerminatedJun 17, 2015Glutathione INHALATIONLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1122-2015Class IITerminatedJun 17, 2015Glutathione INHALATIONLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1121-2015Class IITerminatedJun 17, 2015Bimix (PHENTLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1120-2015Class IITerminatedJun 17, 2015Avastin, solutionLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1119-2015Class IITerminatedJun 17, 2015AlprostadilLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1118-2015Class IITerminatedJun 17, 2015AlprostadilLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1117-2015Class IITerminatedJun 17, 2015Nifedipine Extended-Release TabletsFailed Dissolution Specifications: High out of specification dissolution result at 1 hour time point.Valeant Pharmaceuticals North America LLC · D-1116-2015Class IIITerminatedJun 10, 2015Cetirizine HCl Chewable TabletFailed Impurities/Degradation Specifications: An out of specification (OOS) result was reported for impurity at the 21 month stability time point.Sandoz, Inc · D-1115-2015